Shenzhen Shenxin Biotechnology Co., Ltd
Clinical trials sponsored by Shenzhen Shenxin Biotechnology Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New mRNA vaccine takes aim at RSV in early human trial Results expected Apr 2027 (estimated)
-
New mRNA vaccine aims to shield against RSV
Vaccine Not yet recruitingThis study tests a new mRNA vaccine called IN006 to see if it is safe and helps the body fight RSV, a virus that can cause serious breathing problems. About 200 healthy adults, both younger (18-59) and older (60-79), will receive one or two shots of the vaccine or a placebo. Rese…
Phase 1 • Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd • Aim: Vaccine
Last updated Jun 27, 2026 12:06 UTC
-
MRNA vaccine aims to prevent shingles in older adults
Vaccine Not yet recruitingThis phase 2 trial tests a new mRNA vaccine called IN001 for preventing shingles in healthy adults aged 50 to 79. Researchers will compare three dose levels of IN001 against the existing Shingrix vaccine to see how safe and effective they are. The study involves 480 participants …
Phase 2 • Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd • Aim: Vaccine
Last updated Jun 27, 2026 07:54 UTC